3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
12
Carcinoma, Hepatocellular
7
Neoplasm Metastasis
5
Colorectal Neoplasms
5
Esophageal Squamous Cell Carcinoma
4
Advanced Solid Tumor
4
Solid Tumor
3
Small Cell Lung Carcinoma
3
Lung Neoplasms
3
Esophageal Neoplasms
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Rectal Neoplasms
2
Melanoma
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Advanced Solid Tumour
2
Unresectable Stage III Non-small Cell Lung Cancer
1
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Simpson-Golabi-Behmel syndrome
1
Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Nasopharyngeal Carcinoma
1
Metastatic Solid Tumors
1
Interventions
durvalumab
9
Bevacizumab
8
tremelimumab
4
lenvatinib
3
atezolizumab
3
Nivolumab
3
Ipilimumab
3
fludarabine
2
Magnetic Resonance Imaging
2
Hepatectomy
2
Gemcitabine
2
Cyclophosphamide
2
Cisplatin
2
trastuzumab deruxtecan
1
toripalimab
1
ropidoxuridine
1
poly ICLC
1
pembrolizumab
1
brodalumab
1
X-Rays
1
Whole Genome Sequencing
1
Technetium Tc 99m Aggregated Albumin
1
Standard of Care
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Radiosurgery
1
Radionuclide Imaging
1
Pregabalin
1
Pluvicto
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
tislelizumab
×
90 days
×
Clear all
No trials found.